期刊文献+

国产吉西他滨联合顺铂治疗复发性乳腺癌的临床观察 被引量:1

Clinical observation of gemcitabine plus cisplatin in the treatment for 36 cases of recurrent breast cancer
下载PDF
导出
摘要 目的观察国产吉西他滨(GEM)联合顺铂(DDP)治疗复发性乳腺癌的疗效及毒副作用。方法采用GEM与DDP联合治疗复发性乳腺癌患者36例。化疗剂量:GEM1000mgm2d1、8静滴;DDP25mgm2d1~3静滴;21天为一个周期,至少治疗两周期。结果CR3例,PR17例,SD10例,PD6例,总有效率(CR+PR)55.55%。毒副作用主要为骨髓抑制,恶心、呕吐等。白细胞及血小板减少的发生率分别为61.11%和58.33%,恶心、呕吐发生率为61.11%。结论GEM联合DDP治疗复发性乳腺癌疗效好,毒副作用可耐受,有较好的临床应用价值。 Objective To evaluate the efficacy and toxicity of combined chemotherapy with gemcitabine (GEM) plus cisplatin (DDP) in the treatment of recurrent breast cancer. Methods Thirty- six patients with recurrent breast cancer were enrolled for this study. GEM were administered 1 000 mg/m^2 on day 1,8 ; DDP 25 mg/m^2 on day 1 ~ 3, which was recycled every 3 weeks and with at least 2 cycles. Results Among 36 patients, 3 patients achieved completed response, 17 patients achieved partial response, 10 patients achieved stable disease and 6 patients achieved progressive disease. The overall response rate is 55.55 %. The main tox- icities were myelosuppression, nausea and vomiting. Leukopenia accounted for 61.11%, thrombocytopenia accounted for 58.33 %, nausea and vomiting accounted for 61.11%. Conclusion The schedule of gemcitabine plus cisplatin in the treatment for 36 cases of recurrent breast cancer has good clinical efficacy and tolerability, the regimen could be quite clinically valuable.
作者 庞慧 蔡莉
出处 《实用肿瘤学杂志》 CAS 2006年第4期278-279,共2页 Practical Oncology Journal
关键词 吉西他滨 顺铂 联合化疗 复发性乳腺癌 Gemcitabine Cisplatin Combined chemotherapy Recurrent breast cancer
  • 相关文献

参考文献6

  • 1Spiellmen M,Lombart Cussac,Kalla S,et al.Single agent gemcitabine is active in previously treated metastaic breast cancer[J].Oncology,2001;60:303~307
  • 2Moorsel CJAV,Veeman G,Bergman AM,et al.Combination chemotherapy studies with gemcitabine[J].Semin Oncl,1997;24(17):17
  • 3Rha SY,Jeung H,Kim Y,et al.Efficacy of gemcitabine as a salvage treatment in breast cancer patients refractory to anthracycline and paclintaxel based regimen[J].Proc ASCO,2002;21:2038
  • 4Nagourney RA.Gemcitabine plus cisplatin in breast cancer[J].Oncology (Hunting),2001;15(2):28~33
  • 5Nagourney RA,Link JS,Blitzer J,et al.Gemcitabine plus cisplatin repeating doublet therapy in previously treated,relapsed breast cancer patients[J].J Clin Oncol,2000;15(11):2245~2249
  • 6Doroshow J,Tetef M,Margoclin K,et al.Significant activity of gemcitabine (GEM) and cisplatin (DDP) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (MBC) patients (Pts):a california cancer consortium/loyola univ[J].Chicago Trial.Proc ASCO,2000;19:609

同被引文献4

  • 1黄普文,卢凯华,束永前,王榕生,朱陵君,王建,刘凌翔,穆庆霞.以吉西他滨为主的联合化疗方案治疗晚期乳腺癌的疗效评价[J].临床肿瘤学杂志,2007,12(2):94-96. 被引量:10
  • 2Demiray M, Kurt E, Evrensel T, et al. Phase study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure. Cancer Invest, 2005, 23: 386-391.
  • 3Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. Clin Oncol, 2008, 26: 3950-3957.
  • 4周际昌主编.实用肿瘤内科学.北京:人民卫生出版社,2005:45-48.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部